



## References

1. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997;337(6):373-81.
2. Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluckman E. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet 1995;346(8969):214-9.
3. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001;344(24):1815-22.
4. Barker JN, Wagner JE. Umbilical cord blood transplantation: current state of the art. Curr Opin Oncol 2002;14(2):160-4.
5. Armitage JO. Bone marrow transplantation. N Engl J Med 1994;330(12):827-38.
6. Heldal D, Tjonnfjord G, Brinch L, Albrechtsen D, Egeland T, Steen R, et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 2000;25(11):1129-36.
7. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000;355(9211):1231-7.
8. Champlin RE, Schmitz N, Horowitz MM, Chappuis B, Chopra R, Cornelissen JJ, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000;95(12):3702-9.
9. Platzbecker U, Prange-Krex G, Bornhauser M, Koch R, Soucek S, Aikele P, et al. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 2001;41(2):184-9.

10. Locatelli F, Rocha V, Chastang C, Arcese W, Michel G, Abecasis M, et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. Blood 1999;93(11):3662-71.
11. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998;339(22):1565-77.
12. Wagner JE, Rosenthal J, Sweetman R, Shu XO, Davies SM, Ramsay NK, et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996;88(3):795-802.
13. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996;335(3):157-66.
14. Laporte JP, Gorin NC, Rubinstein P, Lesage S, Portnoi MF, Barbu V, et al. Cord-blood transplantation from an unrelated donor in an adult with chronic myelogenous leukemia. N Engl J Med 1996;335(3):167-70.
15. Mayani H, Lansdorp PM. Biology of human umbilical cord blood-derived hematopoietic stem/progenitor cells. Stem Cells 1998;16(3):153-65.
16. Wognum AW, Eaves AC, Thomas TE. Identification and isolation of hematopoietic stem cells. Arch Med Res 2003;34(6):461-75.
17. Spangrude GJ, Johnson GR. Resting and activated subsets of mouse multipotent hematopoietic stem cells. Proc Natl Acad Sci U S A 1990;87(19):7433-7.
18. Huang S, Terstappen LW. Lymphoid and myeloid differentiation of single human CD34+, HLA-DR+, CD38- hematopoietic stem cells. Blood 1994;83(6):1515-26.
19. Hao QL, Shah AJ, Thiemann FT, Smogorzewska EM, Crooks GM. A functional comparison of CD34 + CD38- cells in cord blood and bone marrow. Blood 1995;86(10):3745-53.
20. Berenson RJ, Andrews RG, Bensinger WI, Kalamasz D, Knitter G, Buckner CD, et al. Antigen CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest 1988;81(3):951-5.

- 21.Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 1996;273(5272):242-5.
- 22.Sato T, Laver JH, Ogawa M. Reversible expression of CD34 by murine hematopoietic stem cells. Blood 1999;94(8):2548-54.
- 23.Nakamura Y, Ando K, Chargui J, Kawada H, Sato T, Tsuji T, et al. Ex vivo generation of CD34(+) cells from CD34(-) hematopoietic cells. Blood 1999;94(12):4053-9.
- 24.Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996;183(4):1797-806.
- 25.Goodell MA, Rosenzweig M, Kim H, Marks DF, DeMaria M, Paradis G, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997;3(12):1337-45.
- 26.Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997;90(12):5013-21.
- 27.Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90(12):5002-12.
- 28.de Wynter EA, Buck D, Hart C, Heywood R, Coutinho LH, Clayton A, et al. CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors. Stem Cells 1998;16(6):387-96.
- 29.Strauss LC, Rowley SD, La Russa VF, Sharkis SJ, Stuart RK, Civin CI. Antigenic analysis of hematopoiesis. V. Characterization of My-10 antigen expression by normal lymphohematopoietic progenitor cells. Exp Hematol 1986;14(9):878-86.
- 30.Craig W, Kay R, Cutler RL, Lansdorp PM. Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med 1993;177(5):1331-42.

31. Terstappen LW, Huang S, Safford M, Lansdorp PM, Loken MR. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. Blood 1991;77(6):1218-27.
32. Brandt J, Briddell RA, Srouf EF, Leemhuis TB, Hoffman R. Role of c-kit ligand in the expansion of human hematopoietic progenitor cells. Blood 1992;79(3):634-41.
33. Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci U S A 1992;89(7):2804-8.
34. Udomsakdi C, Eaves CJ, Sutherland HJ, Lansdorp PM. Separation of functionally distinct subpopulations of primitive human hematopoietic cells using rhodamine-123. Exp Hematol 1991;19(5):338-42.
35. Ladd AC, Pyatt R, Gothot A, Rice S, McMahan J, Traycoff CM, et al. Orderly process of sequential cytokine stimulation is required for activation and maximal proliferation of primitive human bone marrow CD34+ hematopoietic progenitor cells residing in G0. Blood 1997;90(2):658-68.
36. Larochelle A, Vormoor J, Hanenberg H, Wang JC, Bhatia M, Lapidot T, et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med 1996;2(12):1329-37.
37. Metcalf D. Hematopoietic regulators: redundancy or subtlety? Blood 1993;82(12):3515-23.
38. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993;81(11):2844-53.
39. Moore MA, Hoskins I. Ex vivo expansion of cord blood-derived stem cells and progenitors. Blood Cells 1994;20(2-3):468-79; discussion 479-81.
40. Shah AJ, Smogorzewska EM, Hannum C, Crooks GM. Flt3 ligand induces proliferation of quiescent human bone marrow CD34+CD38- cells and maintains progenitor cells in vitro. Blood 1996;87(9):3563-70.
41. Piacibello W, Sanavio F, Garetto L, Severino A, Bergandi D, Ferrario J, et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 1997;89(8):2644-53.

42. Piacibello W, Sanavio F, Severino A, Dane A, Gammaitoni L, Fagioli F, et al. Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. Blood 1999;93(11):3736-49.
43. Kobari L, Pflumio F, Giarratana M, Li X, Titeux M, Izac B, et al. In vitro and in vivo evidence for the long-term multilineage (myeloid, B, NK, and T) reconstitution capacity of ex vivo expanded human CD34(+) cord blood cells. Exp Hematol 2000;28(12):1470-80.
44. Ueda T, Tsuji K, Yoshino H, Ebihara Y, Yagasaki H, Hisakawa H, et al. Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor. J Clin Invest 2000;105(7):1013-21.
45. Kanai M, Hirayama F, Yamaguchi M, Ohkawara J, Sato N, Fukazawa K, et al. Stromal cell-dependent ex vivo expansion of human cord blood progenitors and augmentation of transplantable stem cell activity. Bone Marrow Transplant 2000;26(8):837-44.
46. Rossmann T, Schroder B, Bug G, Muller P, Klenner T, Knaus R, et al. Interleukin 3 improves the ex vivo expansion of primitive human cord blood progenitor cells and maintains the engraftment potential of scid repopulating cells. Stem Cells 2001;19(4):313-20.
47. Yamaguchi M, Hirayama F, Kanai M, Sato N, Fukazawa K, Yamashita K, et al. Serum-free coculture system for ex vivo expansion of human cord blood primitive progenitors and SCID mouse-reconstituting cells using human bone marrow primary stromal cells. Exp Hematol 2001;29(2):174-82.
48. Su RJ, Zhang XB, Li K, Yang M, Li CK, Fok TF, et al. Platelet-derived growth factor promotes ex vivo expansion of CD34+ cells from human cord blood and enhances long-term culture-initiating cells, non-obese diabetic/severe combined immunodeficient repopulating cells and formation of adherent cells. Br J Haematol 2002;117(3):735-46.

49. Kawano Y, Kobune M, Yamaguchi M, Nakamura K, Ito Y, Sasaki K, et al. Ex vivo expansion of human umbilical cord hematopoietic progenitor cells using a coculture system with human telomerase catalytic subunit (hTERT)-transfected human stromal cells. Blood 2003;101(2):532-40.
50. da Silva CL, Goncalves R, Crapnell KB, Cabral JM, Zanjani ED, Almeida-Porada G. A human stromal-based serum-free culture system supports the ex vivo expansion/maintenance of bone marrow and cord blood hematopoietic stem/progenitor cells. Exp Hematol 2005;33(7):828-35.
51. Yonemura Y, Ku H, Lyman SD, Ogawa M. In vitro expansion of hematopoietic progenitors and maintenance of stem cells: comparison between FLT3/FLK-2 ligand and KIT ligand. Blood 1997;89(6):1915-21.
52. Gabbianelli M, Pelosi E, Montesoro E, Valtieri M, Luchetti L, Samoggia P, et al. Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. Blood 1995;86(5):1661-70.
53. Hudak S, Hunte B, Culpepper J, Menon S, Hannum C, Thompson-Snipes L, et al. FLT3/FLK2 ligand promotes the growth of murine stem cells and the expansion of colony-forming cells and spleen colony-forming units. Blood 1995;85(10):2747-55.
54. Jacobsen SE, Okkenhaug C, Myklebust J, Veiby OP, Lyman SD. The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors. J Exp Med 1995;181(4):1357-63.
55. Rusten LS, Lyman SD, Veiby OP, Jacobsen SE. The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro. Blood 1996;87(4):1317-25.
56. Sitnicka E, Lin N, Priestley GV, Fox N, Broudy VC, Wolf NS, et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood 1996;87(12):4998-5005.

57. Ku H, Yonemura Y, Kaushansky K, Ogawa M. Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood 1996;87(11):4544-51.
58. Lyman SD, Jacobsen SE. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998;91(4):1101-34.
59. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991;65(7):1143-52.
60. Rosnet O, Marchetto S, deLapeyriere O, Birnbaum D. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene 1991;6(9):1641-50.
61. Wodnar-Filipowicz A. Flt3 ligand: role in control of hematopoietic and immune functions of the bone marrow. News Physiol Sci 2003;18:247-51.
62. Brasel K, McKenna HJ, Morrissey PJ, Charrier K, Morris AE, Lee CC, et al. Hematologic effects of flt3 ligand in vivo in mice. Blood 1996;88(6):2004-12.
63. Gratwohl A, John L, Baldomero H, Roth J, Tichelli A, Nissen C, et al. FLT-3 ligand provides hematopoietic protection from total body irradiation in rabbits. Blood 1998;92(3):765-9.
64. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994;369(6481):568-71.
65. Alexander WS. Thrombopoietin and the c-Mpl receptor: insights from gene targeting. Int J Biochem Cell Biol 1999;31(10):1027-35.
66. Borge OJ, Ramsfjell V, Cui L, Jacobsen SE. Ability of early acting cytokines to directly promote survival and suppress apoptosis of human primitive CD34+CD38- bone marrow cells with multilineage potential at the single-cell level: key role of thrombopoietin. Blood 1997;90(6):2282-92.
67. Gronthos S, Simmons PJ. The biology and application of human bone marrow stromal cell precursors. J Hematother 1996;5(1):15-23.

68. Waller EK, Olweus J, Lund-Johansen F, Huang S, Nguyen M, Guo GR, et al. The "common stem cell" hypothesis reevaluated: human fetal bone marrow contains separate populations of hematopoietic and stromal progenitors. Blood 1995;85(9):2422-35.
69. Islam A, Glomski C, Henderson ES. Bone lining (endosteal) cells and hematopoiesis: a light microscopic study of normal and pathologic human bone marrow in plastic-embedded sections. Anat Rec 1990;227(3):300-6.
70. Nilsson SK, Dooner MS, Tiarks CY, Weier HU, Quesenberry PJ. Potential and distribution of transplanted hematopoietic stem cells in a nonablated mouse model. Blood 1997;89(11):4013-20.
71. Quesenberry PJ, Crittenden RB, Lowry P, Kittler EW, Rao S, Peters S, et al. In vitro and in vivo studies of stromal niches. Blood Cells 1994;20(1):97-104; discussion 104-6.
72. Moore KA, Ema H, Lemischka IR. In vitro maintenance of highly purified, transplantable hematopoietic stem cells. Blood 1997;89(12):4337-47.
73. Wineman J, Moore K, Lemischka I, Muller-Sieburg C. Functional heterogeneity of the hematopoietic microenvironment: rare stromal elements maintain long-term repopulating stem cells. Blood 1996;87(10):4082-90.
74. Sutherland HJ, Eaves CJ, Lansdorp PM, Thacker JD, Hogge DE. Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells. Blood 1991;78(3):666-72.
75. Henderson AJ, Johnson A, Dorshkind K. Functional characterization of two stromal cell lines that support B lymphopoiesis. J Immunol 1990;145(2):423-8.
76. Breems DA, Blokland EA, Ploemacher RE. Stroma-conditioned media improve expansion of human primitive hematopoietic stem cells and progenitor cells. Leukemia 1997;11(1):142-50.
77. Li J, Sensebe L, Herve P, Charbord P. Nontransformed colony-derived stromal cell lines from normal human marrows. III. The maintenance of hematopoiesis from CD34+ cell populations. Exp Hematol 1997;25(7):582-91.



78. Issaad C, Croisille L, Katz A, Vainchenker W, Coulombel L. A murine stromal cell line allows the proliferation of very primitive human CD34<sup>++</sup>/CD38<sup>-</sup> progenitor cells in long-term cultures and semisolid assays. Blood 1993;81(11):2916-24.
79. Candal FJ, Rafii S, Parker JT, Ades EW, Ferris B, Nachman RL, et al. BMEC-1: a human bone marrow microvascular endothelial cell line with primary cell characteristics. Microvasc Res 1996;52(3):221-34.
80. Castro-Malaspina H, Gay RE, Resnick G, Kapoor N, Meyers P, Chiarieri D, et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 1980;56(2):289-301.
81. Piersma AH, Brockbank KG, Ploemacher RE, van Vliet E, Brakel-van Peer KM, Visser PJ. Characterization of fibroblastic stromal cells from murine bone marrow. Exp Hematol 1985;13(4):237-43.
82. Kuznetsov SA, Friedenstein AJ, Robey PG. Factors required for bone marrow stromal fibroblast colony formation in vitro. Br J Haematol 1997;97(3):561-70.
83. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276(5309):71-4.
84. Caplan AI. The mesengenic process. Clin Plast Surg 1994;21(3):429-35.
85. Conget PA, Minguell JJ. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol 1999;181(1):67-73.
86. Haynesworth SE, Goshima J, Goldberg VM, Caplan AI. Characterization of cells with osteogenic potential from human marrow. Bone 1992;13(1):81-8.
87. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284(5411):143-7.
88. Minguell JJ, Erices A, Conget P. Mesenchymal stem cells. Exp Biol Med (Maywood) 2001;226(6):507-20.
89. Haynesworth SE, Baber MA, Caplan AI. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol 1996;166(3):585-92.
90. Caldwell J, Emerson SG. IL-1 alpha and TNF alpha act synergistically to stimulate production of myeloid colony-stimulating factors by cultured human bone

- marrow stromal cells and cloned stromal cell strains. J Cell Physiol 1994;159(2):221-8.
91. Dalmau SR, Freitas CS, Tabak DG. Interleukin-1 and tumor necrosis factor-alpha as radio- and chemoprotectors of bone marrow. Bone Marrow Transplant 1993;12(6):551-63.
92. Friedenstein AJ. Precursor cells of mechanocytes. Int Rev Cytol 1976;47:327-59.
93. Migliaccio AR, Migliaccio G, Adamson JW, Torok-Storb B. Production of granulocyte colony-stimulating factor and granulocyte/macrophage-colony-stimulating factor after interleukin-1 stimulation of marrow stromal cell cultures from normal or aplastic anemia donors. J Cell Physiol 1992;152(1):199-206.
94. Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP, Gerson SL. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res 2000;9(6):841-8.
95. Gupta P, Oegema TR, Jr., Brazil JJ, Dudek AZ, Slungaard A, Verfaillie CM. Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates: requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteins. Blood 2000;95(1):147-55.
96. Kiger AA, White-Cooper H, Fuller MT. Somatic support cells restrict germline stem cell self-renewal and promote differentiation. Nature 2000;407(6805):750-4.
97. Tran J, Brenner TJ, DiNardo S. Somatic control over the germline stem cell lineage during *Drosophila* spermatogenesis. Nature 2000;407(6805):754-7.
98. Xie T, Spradling AC. A niche maintaining germ line stem cells in the *Drosophila* ovary. Science 2000;290(5490):328-30.
99. Kiger AA, Jones DL, Schulz C, Rogers MB, Fuller MT. Stem cell self-renewal specified by JAK-STAT activation in response to a support cell cue. Science 2001;294(5551):2542-5.
100. Verfaillie CM. Soluble factor(s) produced by human bone marrow stroma increase cytokine-induced proliferation and maturation of primitive hematopoietic

- progenitors while preventing their terminal differentiation. Blood 1993;82(7):2045-53.
- 101.Clausen J, Stockschlader M, Fehse N, Hassan HT, Gabl C, Zander AR. Blood-derived macrophage layers in the presence of hydrocortisone support myeloid progenitors in long-term cultures of CD34+ cord blood and bone marrow cells. Ann Hematol 2000;79(2):59-65.
- 102.Brandt JE, Bartholomew AM, Fortman JD, Nelson MC, Bruno E, Chen LM, et al. Ex vivo expansion of autologous bone marrow CD34(+) cells with porcine microvascular endothelial cells results in a graft capable of rescuing lethally irradiated baboons. Blood 1999;94(1):106-13.
- 103.Xu MJ, Tsuji K, Ueda T, Mukoyama YS, Hara T, Yang FC, et al. Stimulation of mouse and human primitive hematopoiesis by murine embryonic aorta-gonad-mesonephros-derived stromal cell lines. Blood 1998;92(6):2032-40.
- 104.Shih CC, Hu MC, Hu J, Medeiros J, Forman SJ. Long-term ex vivo maintenance and expansion of transplantable human hematopoietic stem cells. Blood 1999;94(5):1623-36.
- 105.Kawada H, Ando K, Tsuji T, Shimakura Y, Nakamura Y, Chargui J, et al. Rapid ex vivo expansion of human umbilical cord hematopoietic progenitors using a novel culture system. Exp Hematol 1999;27(5):904-15.
- 106.Lewis ID, Almeida-Porada G, Du J, Lemischka IR, Moore KA, Zanjani ED, et al. Umbilical cord blood cells capable of engrafting in primary, secondary, and tertiary xenogeneic hosts are preserved after ex vivo culture in a noncontact system. Blood 2001;97(11):3441-9.
- 107.Gammaitoni L, Bruno S, Sanavio F, Gunetti M, Kollet O, Cavalloni G, et al. Ex vivo expansion of human adult stem cells capable of primary and secondary hemopoietic reconstitution. Exp Hematol 2003;31(3):261-70.
- 108.Hao QL, Zhu J, Price MA, Payne KJ, Barsky LW, Crooks GM. Identification of a novel, human multilymphoid progenitor in cord blood. Blood 2001;97(12):3683-90.

109. Storms RW, Goodell MA, Fisher A, Mulligan RC, Smith C. Hoechst dye efflux reveals a novel CD7(+)CD34(-) lymphoid progenitor in human umbilical cord blood. Blood 2000;96(6):2125-33.
110. Canque B, Camus S, Dalloul A, Kahn E, Yagello M, Dezutter-Dambuyant C, et al. Characterization of dendritic cell differentiation pathways from cord blood CD34(+)CD7(+)CD45RA(+) hematopoietic progenitor cells. Blood 2000;96(12):3748-56.



APPENDICES

## APPENDIX

### 1. Phosphate Buffer Saline pH7.2 ( PBS )

Phosphate buffer saline ( PBS ) solution is prepared following the instruction of Biochrome KG ( Germany ) , briefly, the PBS powder is dissolved by 1,000 ml of distilled water, and sterilized by steam autoclave. This solution is stored at 4°C.

### 2. 25X PBS Solution

To prepare 25XPBS solution , follow the formula listed below

NaCl	200.0	g
KCl	5.0	g
Na <sub>2</sub> HPO <sub>4</sub> .12H <sub>2</sub> O	72.4	g
KH <sub>2</sub> PO <sub>4</sub>	5.0	g

All the listed chemical are dissolved in 1,000 ml distilled water , and finally sterilized by steam autoclave. This solution is stored at room temperature.

### 3. 1X PBS Solution

For preparing 1XPBS solution, the 40 ml of PBS solution are dissolved in 940 ml distilled water, sterilized by steam autoclave. This solution is stored in room temperature.

### 4. PBS/2% EDTA

25X PBS	40.0	ml
2%EDTA phenol red	10.0	ml
Distilled water	950.0	ml

This solution is sterilized by steam autoclave, and stored at 4°C.

### 5. 2% EDTA with Phenol Red ( 100X Solution :W/V )

EDTA.Na <sub>2</sub>	10.0	g
Phenol red	100.0	mg
Distilled water	500.0	ml

Gently mixed for fine dissolving, stores at room temperature.

## 6. 0.2% Trypan Blue Dye

Trypan blue dye is used for cell counting in order to exclude dead cells,  
can be prepared by

Physiological saline ( 85% )

NaCl	0.85	g
------	------	---

Distilled water	100.00	ml
-----------------	--------	----

Trypan blue	0.20	g
-------------	------	---

Physiological saline	100.00	ml
----------------------	--------	----

Paper filter before use.



## BIOGRAPHY

Nida pornprasertsud was born on November 30, 1979 in Bangkok, Thailand. She received her Bachelor's Degree of Science in Food Technology, Chulalongkorn University in 2001. She continued her Master's Degree study at Chulalongkorn University in Medical Science Program, in 2002 and completed the program in 2005.